Christian Werner

Mr. Christian Werner

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
CWChristian Werner
Christian Werner
DLDirk Lindenblatt
Dirk Lindenblatt
KVKaido Viht
Kaido Viht
AUAsko Uri
Asko Uri
Karsten NiefindKarsten Niefind
Karsten Niefind
The structural knowledge about protein kinase CK2 is dominated by crystal structures of human CK2α, the catalytic subunit of human CK2, and the product of the CSNK2A1 gene. In contrast, far fewer structures of CK2α′, its paralogous isoform and the product of the CSNK2A2 gene, have been published. However, according to a PDB survey, CK2α′ is the superior alternative for crystallographic studies because of the inherent potential of the single mutant CK2α′Cys336Ser to provide crystal structures with atomic resolution. In particular, a triclinic crystal form of CK2α′Cys336Ser is a robust tool to determine high-quality enzyme-ligand complex structures via soaking. In this work, further high-resolution CK2α′Cys336Ser structures in complex with selected ligands emphasizing this trend are described. In one of these structures, the “N-terminal segment site”, a small-molecule binding region never found in any eukaryotic protein kinase and holding the potential for the development of highly selective substrate-competitive CK2 inhibitors, was discovered. In order to also address the binding site for the non-catalytic subunit CK2β, which is inaccessible in these triclinic CK2α′Cys336Ser crystals for small molecules, a reliable path to a promising monoclinic crystal form of CK2α′Cys336Ser is presented. In summary, the quality of CK2α′Cys336Ser as an exquisite crystallographic tool is solidified.

1 March 2025 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
CWChristian Werner
Christian Werner
SESophia Eimermacher
Sophia Eimermacher
HHHugo Harasimowicz
Hugo Harasimowicz
DFDietmar Fischer
Dietmar Fischer
MPMarkus Pietsch
Markus Pietsch
Karsten NiefindKarsten Niefind
Karsten Niefind
Protein kinase CK2 (casein kinase 2) mainly exists as heterotetrameric holoenzyme with two catalytic subunits (CK2α or CK2α′) bound to a homodimer of non-catalytic subunits (CK2β). With CSNK2A1 and CSNK2A2, the human genome contains two paralogs encoding catalytic CK2 subunits. Both gene products, called CK2α and CK2α′, strongly interact with CK2β. An earlier report that CK2α′ has a lower CK2β affinity than CK2α is confirmed via isothermal titration calorimetry in this study. Furthermore, we show with a fluorescence-anisotropy assay that a CK2β-competitive peptide binds less strongly to CK2α′ than to CK2α. The reason for the reduced affinity of CK2α′ to CK2β and CK2β competitors is puzzling: both isoenzymes have identical amino acid compositions at their CK2β interfaces, but the β4β5 loop, a component of this interface, is conformationally less adaptable in CK2α′ than in CK2α due to intramolecular constraints. To release these constraints, we constructed a CK2α′ mutant that was equalized to CK2α at the backside of the β4β5 loop. Concerning thermostability, affinity to CK2β or CK2β competitors and 3D-structure next to the β4β5 loop, this CK2α′ mutant is more similar to CK2α than to its own wild-type, suggesting a critical role of the β4β5 loop adaptability for CK2β affinity.

1 March 2025 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
CMChristelle Marminon
Christelle Marminon
CWChristian Werner
Christian Werner
AGAlexander Gast
Alexander Gast
LHLars Herfindal
Lars Herfindal
JCJohana Charles
Johana Charles
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
Protein kinase CK2 is a promising therapeutic target, especially in oncology. Over the years, various inhibitors have been developed, with polyhalogenated scaffolds emerging as a particularly effective class. Halogens like bromine and chlorine enhance inhibitor stability by forming additional interactions within the ATP pocket. Among halogenated scaffolds, benzotriazole and benzimidazole have led to potent molecules such as 4,5,6,7-tetrabromo-1H-benzotriazole (IC50 = 300 nM) and 4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazole (IC50 = 140 nM). Modifications, including 4,5,6-tribromo-7-ethyl-1H-benzotriazole (IC50 = 160 nM), further improved activity. Changing scaffolds while retaining halogens has enabled design of new inhibitors. Flavonols, dibenzofuranones, and the indeno[1,2-b]indole scaffold are key examples. Halogenation of the reference molecule 5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4b, IC50 = 360 nM) significantly boosted potency. The study focused on introducing four halogens, yielding to the compound 1,2,3,4-tetrabromo-5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (MC11), with an IC50 of 16 nM. Co-crystallography revealed how bromine atoms enhance binding, and MC11 demonstrated strong in cellulo activity, particularly against leukemic cell lines like IPC-Bcl2.

4 January 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
CWChristian Werner
Christian Werner
TBTatjana Barthel
Tatjana Barthel
HHHugo Harasimowicz
Hugo Harasimowicz
CMChristelle Marminon
Christelle Marminon
MWManfred S. Weiss
Manfred S. Weiss
Karsten NiefindKarsten Niefind
Karsten Niefind
CK2α and CK2α’, two paralogous members of the human kinome, are catalytic subunits of protein kinase CK2. Together with the regulatory subunit CK2β, they form heterotetrameric holoenzymes. CK2 is the subject of efforts to develop effective and selective inhibitors. For this, secondary binding sites remote from the canonical ATP/GTP cavity are critical. A crystallographic fragment screening with CK2α’ crystals and an established molecular fragment collection was performed to identify new ligands at known or novel sites. It resulted in fourteen CK2α’/fragment structures. Five fragments were found at the CK2β interface of CK2α’ and three fragments at the established αD pocket, which exhibits subtle differences between CK2α and CK2α’; comparative co-crystallisations with CK2α showed that one of them binds to the αD pocket of CK2α’ exclusively. No fragments bound at the substrate-binding region of CK2α’, but a CK2α’ structure with dp10, a decameric section of the substrate-competitive inhibitor heparin, and the indenoindole-type ATP-competitive inhibitor 4w was determined. A comparison with a published CK2α/dp10 structure revealed features consistent with reports about substrate specificity differences between the isoenzymes: dp10 binds to CK2α’ and CK2α with opposite strand orientations, and the local conformations of the isoenzymes in the helix αD region are significantly different.

3 August 2026 in Archiv der Pharmazie
Verified
Journal Article
Open access
PDF file
MGMatheus M. Guimarães
Matheus M. Guimarães
CWChristian Werner
Christian Werner
BLBelen Leroy
Belen Leroy
JCJohana Charles
Johana Charles
JGJean Guillon
Jean Guillon
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
Protein kinase CK2 is the subject of numerous studies in medicinal chemistry due to its involvement in the development of several diseases, primarily cancers. Its overexpression in tumor cells is related to key processes such as tumor immune evasion and cell proliferation. The scientific approach of this study aims to investigate the thermal shift assay (TSA) as a pre‐screening tool and to complement it with a co‐crystallization approach in post‐screening. Therefore, the synthesis of seven small‐molecule CK2 inhibitors derived from indeno[1,2‐ b ]indoles was supplemented by 18 related derivatives from our in‐house compound library. The 25 molecules belong to four sub‐scaffolds, namely 4 b ,9 b ‐dihydroxy‐4 b ,5,6,7,8,9 b ‐hexahydroindeno[1,2‐ b ]indole‐9,10‐dione (D‐0), 5,6,7,8‐tetrahydroindeno[1,2‐ b ]indole‐9,10‐dione (D‐1), 9‐hydroxy‐5 H ‐indeno[1,2‐ b ]indol‐10‐one (D‐2), and 5 H ‐indeno[1,2‐ b ]indole‐6,9,10‐trione (D‐3). The most active CK2 inhibitors identified by capillary electrophoresis (CE)‐based assay belong to the D‐1 sub‐scaffold. In the TSA, these compounds also generate significant shifts of the melting temperature (Tm) of CK2, indicating a clear correlation between the results of the CE‐based assay and those of the TSA. The contribution of co‐crystallization in post‐screening also demonstrated the effectiveness of D‐1 sub‐scaffold compared with D‐0 sub‐scaffold.

23 June 2026 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
CWChristian Werner
Christian Werner
SESophia Eimermacher
Sophia Eimermacher
MLMiriam Lauwers
Miriam Lauwers
DLDirk Lindenblatt
Dirk Lindenblatt
ESEsra Seymen
Esra Seymen
MPMarkus Pietsch
Markus Pietsch
A high-throughput screening led to the discovery of cyclic pentapeptides binding to the CK2β-site of both CK2α and CK2α′. These compounds disturb the assembly of both CK2α 2 β 2 and CK2α′ 2 β 2 holoenzymes and induce holoenzyme dissociation.